Biotech

WellteQ Digital Health Inc. (CSE:WTEQ), a leading provider of corporate health and wellness solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL on THURSDAY, APRIL 22 at 8:30AM EST. Scott Montgomery (CEO of WellteQ Digital Health) will be hosting the presentation and answering questions from investors

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model Wellteq currently has two main sectors of customers, employers and insurance companies. Wellteq have secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners like Willis Towers Watson, Advanced Human Imaging and Garmin.

Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VIRTUAL 2021

Date: Thursday, April 22, 2021
Time: 8:30AM Eastern Time (5:30AM Pacific Time)

Webcast: https://www.webcaster4.com/Webcast/Page/2059/40978

If you would like to watch Wellteq's presentation, please make sure you are registered for the virtual event here:

https://planetmicrocapshowcase.com/signup

The Planet MicroCap Showcase: VIRTUAL website is available here:

https://planetmicrocapshowcase.com/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda":

https://planetmicrocapshowcase.com/agenda


News Compliments of Accesswire

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model Wellteq currently has two main sectors of customers, employers and insurance companies. Wellteq have secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN.Network.

If you would like to attend the Planet MicroCap Showcase, please register here:

https://planetmicrocapshowcase.com/signup

Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888 ext

Source:WellteQ Digital Health Inc. via SNN Network



View source version on accesswire.com:
https://www.accesswire.com/641388/Wellteq-Digital-Health-Inc-to-Present-at-the-Planet-Microcap-Showcase-Virtual-on-Thursday-April-22-2021

News Provided by ACCESSWIRE via QuoteMedia

WellteQ Digital Health

WellteQ Digital Health

Overview

In 2020, the COVID-19 global pandemic shook traditional healthcare structures on a worldwide level. Not only did healthcare institutions need integrated systems to manage the influx of patients and personalized information, but companies needed to keep track of the wellness of their teams as large numbers of employees switched to remote work environments.

In this increasingly digital age, the sphere of telemedicine helped to not only revolutionize healthcare navigation but our perception of wellness management. Telemedicine has proven that the world could use innovative digital technologies to not only manage health complications but potentially proactively prevent them. As the global healthcare market is forecasted to grow to nearly US$11.9 trillion by 2022, investing in wellness technology today is investing in the healthcare of tomorrow.

WellteQ Digital Health (CSE:WTEQ) (OTCQB:WTEQF) is a digitally driven health and wellness company aiding the transition from old school healthcare navigation to a more personalized data-driven patient experience. Through data capture, artificial intelligence and analytics solutions, the company seeks to help people take control of their own wellness and overcome accessibility issues around health.

WellteQ customers currently include employers and insurance companies. In December 2020, Singapore reported stress alone can cost companies an estimated US$3.1 billion per year. To prevent such costs and ensure employee success, companies and insurers are making employee health and stress management major priorities for corporate wellness programs.

WellteQ's philosophy emphasizes rethinking wellness through preventative and proactive solutions instead of focusing on the reactionary treatment of health. In 2017, WellteQ partnered with Garmin to receive biometrics from Garmin's wearable biotech and incorporate that data into its advanced wellness portal and analytic solutions. Future generations of this technology combination are expected to support more health and wellness programming.

Operating out of one of the densest population zones in the world, the company also intends on expanding its APAC user base to larger worldwide markets. The completely digitally driven model means unlimited scalability and international localization. Likewise, WellteQ has designed its program to be a multifaceted digital solution that impacts every aspect of healthcare, including mental, behavioral and physiological health.

The company has plans to leverage the positive trends in telemedicine and upgrade its programming for a more unified user experience. The company has plans to upgrade their accessible API architecture to handle more data and integrated device connectivity. This optimization could allow algorithms to create a complete picture of health on an ongoing basis.

The growing WellteQ team consists of passionate professionals dedicated to innovating global health and telemedicine. With experience in commercial, medical and software engineering fields, the diverse team brings world-class expertise that has provided the foundation for its technical growth and economic success.

WellteQ Digital Health's Company Highlights

  • WellteQ is a digitally driven health and wellness company focused on providing users with programs that help them take back control of their health and engage in proactive and preventative wellness measures.
  • The employee wellness app is a software and hardware hybrid that incorporates an intuitive wellness portal with innovative wearables like Garmin, Apple Watch and FitBit.
  • Historically, WellteQ customers have been employers and insurance companies in Asia Pacific markets. The company has significant plans for global expansion with current operations in over 30 countries and counting.
  • WellteQ has partnered with tech giants like Garmin, Myfiziq, i-Screen, Savonix and Doctor Anywhere to create a fully integrated platform that helps track, assess and provide AI-driven analytics for its users and their employers and insurers.
  • Plans for 2021 and 2022 include expanding across the continuum of personalized care with added functions like chronic condition management.
  • Wellteq has signed a perpetual license agreement for sleep chronotype assessments and education content from one of Asia Pacific's leading sleep technology companies.
  • Dr. Peter W. Vaughan, CM, CD, MA, MD, MPH, ICD.D, Chairman of the Board of Directors at WellteQ Digital Health Inc. has been appointed to the Order of Canada.

WellteQ Employee Wellness App

The WellteQ specialized wellness software uses data sources inside the app and from wearable tech to create personalized profiles that coach users through an algorithm for risk-assessment and supportive lifestyle behaviors. This software-hardware hybrid for healthcare management has helped to address the high-demand for personalized and value-added digital health management which has proven to increase employee engagement by 40 percent.

Unlike traditional medical devices, this platform is personalized and customizable to specific wellness goals, and it is available in 13 languages and over 30 countries. WellteQ is committed to scalability in the global corporate wellness industry with plans for further expansion.

In partnership with reputable digital innovation companies, the WellteQ software app employs intelligent digital pathology that tracks key biomarkers for risk assessment, revolutionary 3D body imaging, neurocognitive assessment and virtual consultation functions. Along with additional gamified challenges, this employee smartphone app creates a unified user experience that is accessible on all mobile devices.

In 2021, the company plans on expanding its continuum of personalized care with the introduction of more premium care focused offerings. WellteQ+ will provide chronic condition management and virtual care functions that track chronic illness progression and treatment and monitor patient-specific data, including vitals.

WellteQ Digital Health's Management Team

Scott Montgomery - CEO/ Director/Co-Founder

Scott has performed at the highest level as an athlete, trainer and as a corporate leader for over 17 years having co-built and sold Onsite Health Solutions in 2012 (one of Australia & New Zealand's largest workplace wellness exits). Prior to Onsite, Scott was a Rehabilitation Case Manager with ACC New Zealand, the compulsory personal injury insurance scheme for all of New Zealand. Scott holds a bachelor's degree from the University of Otago.

Jeames Gillett - COO

Jeames brings 15 years of experience within the corporate wellness, insurance and population health sector. Jeames served as National Operations Manager for Onsite Health Solutions. Jeames also served as the National Service Delivery Manager for Vitality Works, a leading provider of Workplace Health Services across Australia & New Zealand. Jeames holds a Bachelor's degree from Stanford University in Exercise Physiology.

Andrew Kerekes - CPO

Andrew has over 20 years of experience in strategy, product design and delivery, sales and transformation. Andrew has held senior leadership positions within GE Capital, the financial services division of General Electric, LiveRamp and EVO, a privately held analytics platform for member health engagement and risk underwriting. Andrew holds a Bachelor's degree from La Trobe University in Psychology & Philosophy.

Daniel Starbuck - CTO

Daniel has over 15 years of experience building scalable enterprise business applications for domestic and international clients from start-ups to Fortune 500 companies. Daniel co-founded CBDS Health (now merged with WellteQ) in 2017.

Olly Bridge - Chief Growth Officer

Mr. Bridge comes to Wellteq from Medibank, Australia's largest health insurer, where he led the design and deployment of both their corporate and retail policy holder digital health and wellness programs. The Medibank digital health program has been deployed to 3.5 million policy holders. Prior to Medibank, Mr. Bridge led the global sales development for Global Corporate Challenge, which when acquired by Virgin Pulse in 2015, was operating in 185 countries around the world. Virgin Pulse are currently the world's largest corporate wellness provider.

Dr. Peter Vaughan - Chairman

Dr. Peter W. Vaughan is Board Chair of Canada Health Infoway and Chair of the Finance and Audit Committee, Treasurer, and Board member of the Supply Chain Advancement Network for Health (SCAN-H) at the University of Windsor Odette School of Business. Dr. Vaughan is former Deputy Minister of Health and Wellness, Province of Nova Scotia, former CEO of South Shore District Health Authority, former President, WebMD Canada, former CEO of the Canadian Medical Association, and former member the Government of Canada's Health/Bioscience Economic Strategy.

Dr Peter Vaughan, has been appointed to the Order of Canada by the Governor General of Canada. The Governor General cited the appointment of Dr Vaughan "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health".

Dr Vaughan, who's career spans medicine, public healthcare, academia and multiple Board and Executive positions is recognized for his tenacious evangelism of healthcare modernization. Dr Vaughan was appointed Chairman of the Board of Directors for Wellteq just prior to the Company's listing on the Canadian Securities Exchange (CSE) in March 2021 and continues to lead the Company's execution to modernize healthcare delivery through the deployment of the Wellteq platform.

Brian Leeners - Co Founder/Director

Brian has been a technology entrepreneur since 1997. In 2007, he founded his first Internet of Things (IoT) company developing sensor and automation solutions for customers including Lowes, Control4, Steelcase and Schneider Electric. Recognizing the opportunity for the IoT in healthcare, Brian co-founded CBDS Health (now merged with WellteQ) in 2017. Brian's boutique venture capital and merchant banking firm has been responsible for +$75 million+ in venture financing.

Jacqueline Yee - Independent Director

Jacqueline has a global track record in mergers and acquisitions and structured finance. She is Managing Director at Macallan Capital, Non Executive Director of Mustang Energy Plc and Treasurer of Kidney Dialysis Foundation in Singapore. Former Financial Working Group Member of the Brain Cancer Foundation in Australia. Previously, signatory Director of BNP Paribas-Fortis United Kingdom and Netherlands and investment banker at Société Générale. Multilingual, a Chartered Accountant in Australia & New Zealand and summa cum laude graduate with Distinction award jointly conferred by the University of Amsterdam Graduate Business School and Graduate Faculty of Economics & Econometrics.

Andrea Johnson - Director

Andrea Johnson is a partner with Dentons Canada LLP and a member of its Canada region board of directors. Her practice focuses on corporate and securities law, with an emphasis on technology and emerging growth companies. Andrea has extensive experience in IPOs, corporate finance, M&A, venture capital and private equity, across sectors including fintech, software, telecommunications and health and life sciences. She has completed the Directors Education Program and is on the Ottawa chapter executive of the Institute for Corporate Directors (ICD). Andrea has received many rankings including from The Best Lawyers in Canada, Lexpert, Acritas, Chambers FinTech and The Legal 500 Canada.

Keep reading...Show less

Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 6, 2022 Deadline in Securities Fraud Class Action against AbbVie, Inc. and Urges Investors with Substantial Losses to Contact the Firm

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against ABBVie, Inc. (ABBVie) ( NYSE: ABBV ) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period").

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES . YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

ROSEN, Top Ranked Investor Counsel, Encourages AbbVie Inc. Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV

 WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ABBVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the "Class Period"), of the important June 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Upcoming Lead Plaintiff Deadline

The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE:ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

TO VIEW OUR COMPLAINT, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: JUNE 6, 2022

CLASS PERIOD: APRIL 30, 2021 through AUGUST 31, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:

James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

ABBVIE'S ALLEGED MISCONDUCT

AbbVie is one of the world's largest pharmaceutical companies. The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales. Rinvoq-an anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes-was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (FDA) to approve Rinvoq for the treatment of several other diseases.

As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz's risk of triggering certain serious side effects. Beginning in February 2019, the FDA repeatedly warned the public that the safety trial indicated that Xeljanz's use could lead to serious heart-related issue, cancer, and other adverse events. Notwithstanding the similarities between Rinvoq and Xeljanz, during the Class Period, Defendants assured investors that Rinvoq was far safer than Xeljanz and not subject to the same regulatory risks.

However, investors began to learn the truth about Rinvoq's significant risks on June 25, 2021, when AbbVie revealed that the FDA was delaying its review of expanded treatment applications for Rinvoq due to the safety concerns associated with Xeljanz. On this news, the price of AbbVie common stock declined $1.76 per share, or approximately 1.5%, from a close of $114.74 per share on June 24, 2021, to close at $112.98 per share on June 25, 2021.

Then, on September 1, 2021, the FDA announced that final results from the Xeljanz safety trial established an increased risk of serious adverse events, even with low doses of Xeljanz. As a result, the FDA determined that it would require new and updated warnings for Xeljanz and Rinvoq because Rinvoq "share[s] similar mechanisms of action with Xeljanz" and "may have similar risks as seen in the Xeljanz safety trial." The FDA also indicated that it would further limit approved indications for Rinvoq as a result of these safety concerns. On this news, the price of AbbVie common stock declined $8.51 per share, or more than 7%, from a close of $120.78 per share on August 31, 2021, to close at $112.27 per share on September 1, 2021.

After the Class Period, on December 3, 2021, AbbVie announced that the FDA had updated Rinvoq's label to require additional safety warnings and limit marketing of Rinvoq to only its use after treatment with other drugs has failed. On January 11, 2022, Defendants admitted that these changes to Rinvoq's label would negatively impact sales, forcing the Company to reduce its long-term guidance for Rinvoq's sales in 2025.

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

WHAT CAN I DO?

AbbVieinvestors may, no later than June 6, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLPor other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages AbbVie investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP



View source version on accesswire.com:
https://www.accesswire.com/702143/CLASS-ACTION-ALERT-Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc-Investors-of-Upcoming-Lead-Plaintiff-Deadline

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: ABBV NTRA MULN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

AbbVie Inc. (NYSE:ABBV)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=27532&wire=1
Lead Plaintiff Deadline: June 6, 2022
Class Period: April 30, 2021 - August 31, 2021

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: AUPH LILM AXSM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association Congress

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals

In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×